Search results

• Why invest in Croda?

  Discover why investing in Croda offers long-term growth, innovation-led performance, and sustainable value across global specialty chemicals markets.

• 2025 Annual Report

  Croda’s 2025 Annual Report allows you to explore our financial performance, strategic progress, sustainability highlights, and innovation driving long-term growth.

• Chairs statement 2025

  A message from the Chair, Danuta Gray, highlighting the company’s performance, strategic progress, governance priorities, and outlook for sustainable growth in the year ahead.

• Chief Executive's Statement 2025

  An overview from Steve Foots, our Chief Executive, outlining the year’s key achievements, business performance, strategic priorities, and future outlook for growth and innovation.

• Croda Foundation

  Introduction to the Croda Foundation, the independently managed, philanthropic arm of Croda International.

• Croda acquires innovative seed enhancement company Incotec

  Operating in one of the fastest growing segments within the crop care market, Incotec develop and supply a wide range of proprietary and sustainable technologies for both vegetable seeds and field crops.

• Acquisition of Iberchem expands reach into high growth fragrances market

  Acquiring the entire issued share capital of Fragrance Spanish Topco, S.L., trading as Iberchem (“the acquisition”), a leading global fragrances and flavours (“F&F”) company.

• Strengthening Life Sciences with the acquisition of Avanti Polar Lipids

  A leader in drug delivery systems for next generation pharmaceuticals, the acquisition more than doubles Croda’s research and development (R&D) capability in drug delivery.

• Strategic investment Entekno Materials

  A new Smart Partnership focused on the development of a new particle technology that will deliver superior protection benefits to the sun care and personal care markets.

• Acquisition of global vaccine adjuvant specialist

  Vaccine adjuvants are a natural extension to Croda’s market leading, high-purity excipient delivery systems in its Health Care business., these adjuvants represent a niche, high-growth market.

• Vietnam

  Croda’s Vietnam office was founded in 2012 and is located in Ho Chi Minh City.

• Our heritage

  Founded in 1925, we continue to build on our heritage every day, with sustainability always central to our thinking, turning exciting and often ground-breaking ideas into practical solutions for our customers.

• Croda announces brand evolution to mark centenary year animation Page Summary Title

  Croda announces brand evolution to mark centenary year animation Page Summary Description

• Annual Report archive

  Annual reports from previous years.

• Croda Half Year Results fireside chat with Morgan Stanley

  Watch our fireside chat with Morgan Stanley from 29 July 2025.

• Analyst consensus

  Consensus collated from estimates submitted by side-sell analysts on Croda International Plc.

• PTIC divestment

  View the full webinar from the 22 December 2021 discussing the agreement to divest the majority of our PTIC businesses to Cargill Inc.

• Third quarter trading update

  Update on trading from 01 July to 30 September 2023

• Half year 2024 results

  Group performance in line with expectations reflecting more stable market conditions and operational progress

• UK Government to support expansion of Croda's lipid systems manufacturing facility

  31 March 2022: This investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines.